P42 The age-related ER+PR+ expression differs by HER-2/neu status
HongYun Huang, Marie-Rose Christiaens(Pomeranian Medical University), Frédéric Amant(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), E. Van Limbergen(Maastricht University Medical Centre), Patrick Berteloot(KU Leuven), Robert Paridaens(Cornell University), Ruth Achten(Jessa Hospital), M. Drijkoningen(Institut Scientifique de Santé Publique), I. Vergote, P. Neven(Universitair Ziekenhuis Leuven)
Cited by 0
Related Papers
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer
|International Journal of Gynecological Cancer|2015|757
Oxidative Stress and Oval Cell Accumulation in Mice and Humans with Alcoholic and Nonalcoholic Fatty Liver Disease
|American Journal Of Pathology|2003|448